Central Research Institute of Epidemiology, 111123 Moscow, Russia.
Viroscience Department, Erasmus Medical Centre, 3015 CE Rotterdam, The Netherlands.
Viruses. 2020 Jul 31;12(8):838. doi: 10.3390/v12080838.
The increasing use of the integrase strand transfer inhibitor (INSTI) class for the treatment of HIV-infection has pointed to the importance of analyzing the features of HIV-1 subtypes for an improved understanding of viral genetic variability in the occurrence of drug resistance (DR). In this study, we have described the prevalence of INSTI DR in a Russian cohort and the genetic features of HIV-1 integrase sub-subtype A6. We included 408 HIV infected patients who were not exposed to INSTI. Drug resistance mutations (DRMs) were detected among 1.3% of ART-naïve patients and among 2.7% of INSTI-naïve patients. The prevalence of 12 polymorphic mutations was significantly different between sub-subtypes A6 and A1. Analysis of the genetic barriers determined two positions in which subtype A (A1 and A6) showed a higher genetic barrier (G140C and V151I) compared with subtype B, and one position in which subtypes A1 and B displayed a higher genetic barrier (L74M and L74I) than sub-subtype A6. Additionally, we confirmed that the L74I mutation was selected at the early stage of the epidemic and subsequently spread as a founder effect in Russia. Our data have added to the overall understanding of the genetic features of sub-subtype A6 in the context of drug resistance.
越来越多的人将整合酶抑制剂(INSTI)类药物用于治疗 HIV 感染,这凸显了分析 HIV-1 亚型特征的重要性,以便更好地了解耐药性(DR)发生时病毒遗传变异性。在这项研究中,我们描述了俄罗斯队列中 INSTI 耐药的流行情况以及 HIV-1 整合酶亚亚型 A6 的遗传特征。我们纳入了 408 名未接触过 INSTI 的 HIV 感染患者。在未接受 ART 治疗的患者中,有 1.3%检测到耐药突变(DRMs),而在未接受 INSTI 治疗的患者中,有 2.7%检测到耐药突变。亚亚型 A6 和 A1 之间 12 个多态性突变的流行率存在显著差异。遗传障碍分析确定了两个位置,其中亚亚型 A(A1 和 A6)与亚亚型 B 相比显示出更高的遗传障碍(G140C 和 V151I),而亚亚型 A1 和 B 与亚亚型 A6 相比显示出更高的遗传障碍(L74M 和 L74I)。此外,我们还证实,L74I 突变是在流行早期选择的,随后作为俄罗斯的一个创始效应传播。我们的数据增加了对耐药性背景下亚亚型 A6 遗传特征的整体理解。